Company intelligence / Profile preview

MaCHS

Ownership: Private
Development stage: Other

Overview

MaCHS is a biotechnology company focused on developing next-generation macrophage-targeted cancer immunotherapies. The company's proprietary platform leverages the unique biology of macrophages to reprogram the tumor microenvironment from immunosuppressive to immunostimulatory. By targeting specific macrophage populations, MaCHS aims to overcome the limitations of current checkpoint inhibitors and improve outcomes for patients with hard-to-treat solid tumors. Their approach includes both cell-based therapies and small molecule modulators designed to activate the innate immune system against cancer cells.

Therapeutic areas: Oncology
Modalities: Cell therapyBiologicSmall molecule
Industry: Biotech

Beyond the preview

Go deeper on MaCHS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MaCHS.

Explore the full profile